# A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

> **NCT04392648** · PHASE1 · WITHDRAWN · sponsor: **Teva Branded Pharmaceutical Products R&D LLC**

## Conditions studied

- Relapsed and/or Refractory Multiple Myeloma

## Interventions

- **DRUG:** TAK-573
- **DRUG:** Pomalidomide
- **DRUG:** Bortezomib
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04392648
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-06-24
- **Primary completion:** 2023-11-10
- **Final completion:** 2023-11-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business Decision (no enrollment)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04392648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04392648, "A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT04392648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*